Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,563.10
(
-0.66%
)
US TECH 100
23,508.00
(
-0.90%
)
Dow Jones
45,838.12
(
-0.40%
)
Brent Oil
106.86
(
2.32%
)
Bitcoin
70,067.00
(
0.24%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 171496

Saturday, 12/21/2013 6:37:34 PM

Saturday, December 21, 2013 6:37:34 PM

Post# of 257262
Copy editor needed immediately:

http://www.bizjournals.com/boston/blog/bioflash/2013/12/gilead-says-it-will-target-the-same.html

Gilead said today that based on promising data from a late-stage study of its drug, Sovaldi, it plans to apply for U.S. approval by the end of March for the drug as part of a regiment to treat hepatitis C genotype 1…

… Enanta’s stock fell double digits today on the news coming out of Gilead…

…Enanta is still the most successful of all the local biotechs that went public in 2013, with its stock price more than doubling since its March IPO.

At least the final paragraph is error-free, LOL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today